Immunological consequences following splenectomy in patients with liver cirrhosis

Hirakawa,Yusuke; Ogata,Toshiro; Sasada,Tetsuro; Yamashita,Takuto; Itoh,Kyogo; Tanaka,Hiroyuki; Okuda,Koji

doi:10.3892/etm.2019.7640

Immunological consequences following splenectomy in patients with liver cirrhosis

Authors:
- Yusuke Hirakawa
- Toshiro Ogata
- Tetsuro Sasada
- Takuto Yamashita
- Kyogo Itoh
- Hiroyuki Tanaka
- Koji Okuda
View Affiliations

Affiliations: Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Cancer Vaccine Center, Kurume University, Kurume, Fukuoka 839-0863, Japan, Biostatistics Center, Kurume University, Kurume, Fukuoka 830-0011, Japan
Published online on: June 3, 2019 https://doi.org/10.3892/etm.2019.7640
Pages: 848-856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The immune status in patients with liver cirrhosis is generally impaired due to concomitant hypersplenism. As the spleen is the largest lymphoid organ, deleterious events resulting from splenectomy are of concern in these patients. However, the immunological consequences after splenectomy have not yet been fully elucidated. In the present study, the immune status after splenectomy was comprehensively examined. Splenectomy was performed in 11 patients with liver cirrhosis and hypersplenism, and the immune status in peripheral blood was examined and compared before and at 1, 3 and 6 months after splenectomy. Splenectomy significantly lowered the neutrophil‑to‑lymphocyte ratio, due to a surge in lymphocytes in the peripheral circulation at 3 and 6 months after splenectomy. The frequency of cluster of differentiation (CD)4+ T cells decreased after splenectomy, whereas the frequency of CD8+ T cells increased. Notably, the frequencies of the naïve and central memory subsets of CD4+ and CD8+ T cells decreased, whereas those of the effector memory subset trended upward. In addition, the frequencies of other immune cells such as γδ T cells, natural killer T cells and natural killer cells transiently increased, while inhibitory cells such as regulatory T cells and myeloid‑derived suppressor cells significantly decreased. T‑cell responses to viral‑ and tumor‑associated antigens increased after splenectomy in five of eight and two of five patients, respectively. To the best of our knowledge, this is the first study to precisely examine the drastic changes of immunological phenotypes in peripheral blood after splenectomy in patients with cirrhosis. Our findings suggested that splenectomy in patients with cirrhosis may ameliorate the impaired immune status, possibly by reducing suppressive cells and enhancing the effector cell population and function, which could, at least in part, explain the mechanisms responsible for the clinical benefits of splenectomy.

View Figures

View References

1	Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM and Solà R: Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 40:823–830. 2004. View Article : Google Scholar : PubMed/NCBI
2	Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, et al: Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study. Dig Liver Dis. 33:41–48. 2001. View Article : Google Scholar : PubMed/NCBI
3	Nomura Y, Kage M, Ogata T, Kondou R, Kinoshita H, Ohshima K and Yano H: Influence of splenectomy in patients with liver cirrhosis and hypersplenism. Hepatol Res. 44:E100–E109. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wada Y, Nakashima O, Kutami R, Yamamoto O and Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 27:407–414. 1998. View Article : Google Scholar : PubMed/NCBI
5	Okabayashi T and Hanazaki K: Overwhelming postsplenectomy infection syndrome in adults-a clinically preventable disease. World J Gastroenterol. 14:176–179. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kawaguchi T, Kuromatsu R, Ide T, Taniguchi E, Itou M, Sakata M, Abe M, Sumie S and Sata M: Thrombocytopenia, an important interfering factor of antiviral therapy and hepatocellular carcinoma treatment for chronic liver diseases. Kurume Med J. 56:9–15. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ogata T, Okuda K, Sato T, Hirakawa Y, Yasunaga M, Horiuchi H, Nomura Y, Kage M, Ide T, Kuromatsu R, et al: Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia. Kurume Med J. 60:37–45. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hashizume M, Tomikawa M, Akahoshi T, Tanoue K, Gotoh N, Konishi K, Okita K, Tsutsumi N, Shimabukuro R, Yamaguchi S and Sugimachi K: Laparoscopic splenectomy for portal hypertension. Hepatogastroenterology. 49:847–852. 2002.PubMed/NCBI
9	Anegawa G, Kawanaka H, Uehara H, Akahoshi T, Konishi K, Yoshida D, Kinjo N, Hashimoto N, Tomikawa M, Hashizume M and Maehara Y: Effect of laparoscopic splenectomy on portal hypertensive gastropathy in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol. 24:1554–1558. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hu K, Lei P, Yao Z, Wang C, Wang Q, Xu S, Xiong Z, Huang H, Xu R, Deng M and Maehara Y: Laparoscopic RFA with splenectomy for hepatocellular carcinoma. World J Surg Oncol. 14:1962016. View Article : Google Scholar : PubMed/NCBI
11	Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, Harada N, Yamashita Y, Kawanaka H, Nishizak T and Maehara Y: The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. Transpl Int. 21:833–842. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zhang XY, Li C, Wen TF, Yan LN, Li B, Yang JY, Wang WT and Jiang L: Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A casecontrol study. World J Gastroenterol. 21:2358–2366. 2015. View Article : Google Scholar : PubMed/NCBI
13	Halazun KJ, Hardy MA, Rana AA, Woodland DC IV, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, BrownRS Jr and Emond JC: Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 250:141–151. 2009. View Article : Google Scholar : PubMed/NCBI
14	Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K and Torimura T: The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 5:83–88. 2016. View Article : Google Scholar : PubMed/NCBI
15	Kinjo N, Kawanaka H, Akahoshi T, Tomikawa M, Yamashita N, Konishi K, Tanoue K, Shirabe K, Hashizume M and Maehara Y: Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension. Br J Surg. 97:910–916. 2010. View Article : Google Scholar : PubMed/NCBI
16	Roederer M: Spectral compensation for flow cytometry: Visualization artifacts, limitations and caveats. Cytometry. 45:194–205. 2001. View Article : Google Scholar : PubMed/NCBI
17	Dumitru CA, Moses K, Trellakis S, Lang S and Brandau S: Neutrophils and granulocytic myeloid-derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 61:1155–1167. 2012. View Article : Google Scholar : PubMed/NCBI
18	Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Komatsu N, Matsueda S, Sasada T, Yamada A, et al: Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: Dose-related immune boosting and suppression. Cancer Immunol Immunother. 64:493–505. 2015. View Article : Google Scholar : PubMed/NCBI
19	Tang H, Li B, Zhang A, Lu W, Xiang C and Dong J: Prognostic significance of neutrophil-to-lymphocyte ratio in colorectal liver metastasis: A systematic review and meta-analysis. PLoS One. 18:e01594472016. View Article : Google Scholar
20	Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol. 7:2807–2815. 2015. View Article : Google Scholar
21	Min KW, Kwon MJ, Kim DH, Son BK, Kim EK, Oh YH and Wi YC: Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: A better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Sci Rep. 25:139672017. View Article : Google Scholar
22	Mozos I, Malainer C, Horbańczuk J, Gug C, Stoian D, Luca CT and Atanasov AG: Inflammatory markers for arterial stiffness in cardiovascular diseases. Front Immunol. 8:10582017. View Article : Google Scholar : PubMed/NCBI
23	Mueller SN, Gebhardt T, Carbone FR and Heath WR: Memory T cell subsets, migration patterns and tissue residence. Annu Rev Immunol. 31:137–161. 2013. View Article : Google Scholar : PubMed/NCBI
24	Groot F, van Capel TM, Schuitemaker J, Berkhout B and de Jong EC: Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology. 3:522006. View Article : Google Scholar : PubMed/NCBI
25	Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S and Bronte V: Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2:628–639. 2012. View Article : Google Scholar : PubMed/NCBI
26	Levy L, Mishalian I, Bayuch R, Zolotarov L, Michaeli J and Fridlender ZG: Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology. 4:e9984692015. View Article : Google Scholar : PubMed/NCBI
27	Hashimoto N, Shimoda S, Kawanaka H, Tsuneyama K, Uehara H, Akahoshi T, Kinjo N, Taketomi A, Shirabe K, Akashi K, et al: Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol. 165:243–250. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sumida K, Shimoda S, Iwasaka S, Hisamoto S, Kawanaka H, Akahoshi T, Ikegami T, Shirabe K, Shimono N, Maehara Y, et al: Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C. Clin Exp Immunol. 174:172–178. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
30	Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, Nakagawa H, Iida N, Fushimi K and Kaneko S: Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 65:715–725. 2016. View Article : Google Scholar : PubMed/NCBI
31	Long X, Wang J, Zhao JP, Liang HF, Zhu P, Cheng Q, Chen Q, Wu YH, Zhang ZG, Zhang BX and Chen XP: Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo. J Huazhong Univ Sci Technolog Med Sci. 36:667–676. 2016. View Article : Google Scholar : PubMed/NCBI
32	Huang CH, Jeng WJ, Ho YP, Teng W, Chen WT, Chen YC, Lin SM, Chiu CT, Sheen IS and Lin CY: Increased regulatory T cells in patients with liver cirrhosis correlated with hyperbilirubinemia and predict bacterial complications. J Gastroenterol Hepatol. 30:775–783. 2015. View Article : Google Scholar : PubMed/NCBI
33	Nagai H, Mukouzu T, Matsui D, Kanekawa T, Matsui T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Ishii K, et al: Host Immunity influences the efficacy of combined intra-arterial chemotherapy for advanced hepatocellular carcinoma in liver cirrhosis patients. Hepatogastroenterology. 61:741–746. 2014.PubMed/NCBI
34	Romano A, Hou X, Sertorio M, Dessein H, Cabantous S, Oliveira P, Li J, Oyegue S, Arnaud V, Luo X, et al: Foxp3+regulatory T cells in hepatic fibrosis and splenomegaly caused by schistosoma japonicum: The spleen may be a major source of tregs in subjects with splenomegaly. PLoS Negl Trop Dis. 10:e00043062016. View Article : Google Scholar : PubMed/NCBI
35	Bedard M, Salio M and Cerundolo V: Harnessing the power of invariant natural killer T cells in cancer immunotherapy. Front Immunol. 18:18292017. View Article : Google Scholar
36	Sekiguchi T, Nagamine T, Takagi H and Mori M: Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection. World J Gastroenterol. 7:2089–2094. 2006. View Article : Google Scholar
37	Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T, Habu Y, Nakagawa R, Ami K, Hiraide H and Mochizuki H: Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology. 32:962–969. 2000. View Article : Google Scholar : PubMed/NCBI
38	Yang CM, Yoon JC, Park JH and Lee JM: Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. PLoS One. 14:e01757932017. View Article : Google Scholar
39	Poli A, Michel T, Thérésine M, Andrès E, Hentges F and Zimmer J: CD56bright natural killer (NK) cells: An important NK cell subset. Immunology. 126:458–465. 2009. View Article : Google Scholar : PubMed/NCBI
40	Wang J, Han W, Gao Z, Wang Y, Wu L, Zhang J, Lai W and Wang Z: Elevation of CD16⁺CD56⁺ NK-cells and down-regulation of serum interleukin-21 (IL-21) and IL-1α after splenectomy in relapsed hemophagocytic lymphohistiocytosis of unknown cause. Hematology. 22:477–483. 2017.PubMed/NCBI
41	Goh CC, Roggerson KM, Lee HC, Golden-Mason L, Rosen HR and Hahn YS: Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-γ production by altering cellular metabolism via arginase-1. J Immunol. 196:2283–2292. 2016. View Article : Google Scholar : PubMed/NCBI
42	Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, et al: Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: A randomized, open-label, phase II study. J Gastroenterol. 47:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
43	Sakamaki A, Watanabe T, Abe S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S and Terai S: Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient. Clin J Gastroenterol. 10:261–264. 2017. View Article : Google Scholar : PubMed/NCBI
44	Matsukiyo Y, Nagai H, Matsui T and Igarashi Y: Host immunological effects of partial splenic embolization in patients with liver cirrhosis. J Immunol Res. 2018:17463912018. View Article : Google Scholar : PubMed/NCBI
45	Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, et al: Monitoring regulatory T cells in clinical samples: Consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 64:1271–1286. 2015. View Article : Google Scholar : PubMed/NCBI